Melanoma combination doesn’t meet endpoint

Sunday 23 August 2020
Country

Switzerland

A Phase 3 trial of a prospective triple combination therapy for advanced melanoma failed to meet its primary endpoint of progression free survival, Novartis announced on 22 August. The trial was testing the experimental checkpoint antibody spartalizumab in combination with Tafinlar (dabrafenib) and Mekinist (trametinib), both approved products, in patients with melanoma with a BRAF V600 mutation.